<DOC>
	<DOCNO>NCT00005636</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know cisplatin effective without pemetrexed disodium malignant mesothelioma pleura . PURPOSE : Randomized phase III trial compare effectiveness cisplatin without pemetrexed disodium treat patient malignant mesothelioma pleura remove surgery .</brief_summary>
	<brief_title>Cisplatin With Without Pemetrexed Disodium Treating Patients With Malignant Mesothelioma Pleura That Can Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival patient malignant pleural mesothelioma treat cisplatin without LY231514 . II . Compare duration response , time progression , time treatment failure patient treatment regimen . III . Compare tumor response rate clinical benefit treatment regimens patient . IV . Compare Lung Cancer Symptom Scale score , pulmonary function test score , lung density determination treatment regimens patient . V. Compare toxicity treatment regimens patient . VI . Assess pharmacokinetics vitamin metabolite status treatment regimens patient . OUTLINE : This randomize , single blind , multicenter study . Patients stratify accord performance status ( Karnofsky 70-80 % vs 90-100 % ) , degree measurability ( bidimensional v unidimensional ) , histologic subtype ( epithelial v others ) , WBC ( 8,300/mm3 high v less 8,300/mm3 ) , pain intensity ( low vs high ) , analgesic consumption ( low vs high ) , dyspnea ( low vs high ) , homocysteine ( low vs high ) , gender , country , treatment center . Patients randomize one two treatment arm . Arm I : Patients receive LY231514 IV 10 minute follow cisplatin IV 2 hour day 1 . Arm II : Patients receive cisplatin arm I . Treatment repeat every 21 day least 6 course absence disease progression unacceptable toxicity . Patients follow 4 week , every 3 month thereafter . PROJECTED ACCRUAL : A total 280 patient ( 140 per treatment arm ) accrue study within 15 month .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant mesothelioma pleura amenable curative surgery Must radiologically accessible Unidimensionally bidimensionally measurable disease Pleural effusion positive bone scan consider measurable No brain metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase , AST , ALT great 3.0 time ULN ( great 5 time ULN liver involvement ) Albumin least 3.0 g/dL Renal : Creatinine clearance least 45 mL/min Other : No serious systemic disorder may preclude study No prior primary malignancy within past 5 year except carcinoma situ cervix adequately treat basal cell carcinoma skin No obvious malnourishment great 10 % weight loss within 6 week prior study No active infection Not pregnant nursing Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Prior immunomodulators allow pleurodesis No concurrent immunotherapy Chemotherapy : No prior systemic chemotherapy At least 1 week since prior bleomycin pleurodesis Prior intracavitary cytotoxic drug allow pleurodesis No concurrent chemotherapy Endocrine therapy : No concurrent hormonal anticancer therapy Radiotherapy : At least 4 week since prior radiotherapy target lesion Lesion must clearly progressive No concurrent radiotherapy Surgery : See Disease Characteristics No concurrent surgery cancer Other : At least 4 week since prior investigational agent No concurrent aspirin nonsteroidal antiinflammatory drug 2 day prior 2 day study ( 5 day prior long act agent piroxicam , naproxen , diflunisal , nabumetone ) No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>